Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies

Garuolienė, Kristina; Godman, Brian; Gulbinovič, Jolanta; Schiffers, Krijn; Wettermark, Björn

doi:10.1586/14737167.2016.1158649

Cited by 22 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, rosuvastatin is current subject to 100% co-payment. These findings are similar to other studies where prescribing restrictions have significantly affected statin use [29,[66][67][68]. However, other studies focusing on the implementation of national guidelines for CVD prevention are needed to better understand these results.…”

Section: Discussionsupporting

confidence: 87%

Statin use in Brazil: findings and implications

Nascimento

Guerra

Álvares

et al. 2018

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 87%

Statin use in Brazil: findings and implications

Nascimento

Guerra

Álvares

et al. 2018

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…Overall, accessibility and funding of new medicines does vary among Member States, as seen with the anti-TNF alpha medicines for rheumatoid arthritis and Crohn's disease and new treatments for hepatitis C, depending on available resources. Similarly for existing medicines such as the proton-pump inhibitors and statins with different patient co-payments and prescribing restrictions between countries (Godman et al, 2010 ; Putrik et al, 2014 ; de Bruijn et al, 2016 ; Garuoliene et al, 2016 ; Kostic et al, 2017 ).…”

Section: Framework Initiatives and Tools Supporting The Early Accessmentioning

confidence: 99%

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

et al. 2017

Self Cite

View full text Add to dashboard Cite

Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. However, once medicines are approved through MAPPs, they will be evaluated for funding by payers through different activities. These include Health Technology Assessment (HTA) with often immature clinical data and high uncertainty, financial considerations, and negotiations through different types of agreements, which can require monitoring post launch. Payers have experience with new medicines approved through conditional approval, and the fact that MAPPs present additional challenges is a concern from their perspective. There may be some activities where payers can collaborate. The final decisions on whether to reimburse a new medicine via MAPPs will have more variation than for medicines licensed via conventional processes. This is due not only to increasing uncertainty associated with medicines authorized through MAPPs but also differences in legal frameworks between member states. Moreover, if the financial and side-effect burden from the period of conditional approval until granting full marketing authorization is shifted to the post-authorization phase, payers may have to bear such burdens. Collection of robust data during routine clinical use is challenging along with high prices for new medicines during data collection. This paper presents the concept of MAPPs and possible challenges. Concerns and potential ways forward are discussed and a number of recommendations are presented from the perspective of payers.

show abstract

“…We are also seeing increased use of PPIs among Central and Eastern European (CEE) countries (2). However, this is not universal as there are prescribing restrictions and copayments for PPIs in some CEE countries such as Lithuania and Serbia, which appreciably limited their use versus Western European countries (2,5).…”

Section: Introductionmentioning

confidence: 99%